MECASERMIN for Insulin-like growth factor decreased: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 44 adverse event reports in the FDA FAERS database where MECASERMIN was used for Insulin-like growth factor decreased.
Most Reported Side Effects for MECASERMIN
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 117 | 24.6% | 2 | 23 |
| Headache | 41 | 8.6% | 0 | 4 |
| Hypoglycaemia | 36 | 7.6% | 0 | 17 |
| Blood glucose decreased | 32 | 6.7% | 0 | 0 |
| Drug dose omission | 27 | 5.7% | 0 | 5 |
| Injection site pain | 26 | 5.5% | 0 | 0 |
| Vomiting | 26 | 5.5% | 0 | 5 |
| Fatigue | 25 | 5.3% | 0 | 2 |
| Pyrexia | 23 | 4.8% | 0 | 1 |
| Decreased appetite | 22 | 4.6% | 0 | 5 |
| Product dose omission issue | 22 | 4.6% | 0 | 2 |
| Tonsillar hypertrophy | 22 | 4.6% | 0 | 7 |
| Drug ineffective | 21 | 4.4% | 0 | 1 |
| Malaise | 20 | 4.2% | 0 | 3 |
| Inappropriate schedule of drug administration | 14 | 2.9% | 0 | 1 |
Other Indications for MECASERMIN
Primary insulin like growth factor-1 deficiency (143)
Off label use (112)
Body height below normal (82)
Product use in unapproved indication (55)
Product used for unknown indication (38)
Growth failure (29)
Short stature (29)
Growth hormone deficiency (28)
Severe primary insulin like growth factor-1 deficiency (20)
Product use issue (13)